全球干性老龄化黄斑部病变市场：各地区及国家分析与预测（2025-2035）

干性老龄化黄斑部病变是进行性眼疾，会影响黄斑部（视网膜的中心），损害负责清晰中央视力的区域。

这种疾病会导致中央视野视力逐渐丧失，而中央视野对于阅读、驾驶和识别人脸等日常活动至关重要。

由于几个关键因素，干性老龄化黄斑部病变市场正在经历强劲增长。主要驱动因素之一是全球人口老化。老龄化是导致干性老龄化黄斑部病变最重要的风险因素，随着老年人口的增加，对有效治疗方法和诊断工具的需求也在增加。此外，光同调断层扫瞄（OCT）和眼底照相等视网膜成像诊断技术的进步使得能够更早发现疾病并更准确地了解进展，从而促进了市场的扩张。

此外，人们对精准医疗和基因检测的兴趣日益浓厚，预计将透过针对每位患者量身定制治疗方案来改善临床疗效。此外，人们眼部健康意识的增强、生活习惯的改善以及定期眼部检查等预防措施的扩大也推动了需求。此外，新兴国家医疗基础设施的改善和眼科医生专业培训的普及也促进了创新治疗方法的引入。这些因素结合起来，预计将继续推动干性老龄化黄斑部病变市场的成长。

本报告调查了全球干性老龄化黄斑部病变市场，并总结了主要趋势、影响市场的因素分析、法律制度、技术和专利趋势、案例研究、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局和主要企业的概况。

目录

执行摘要

第一章全球干性老龄化黄斑部病变市场：产业展望

• 市场趋势
• 法律规范
• 干性老龄化黄斑部病变的全球流行病学
• 临床试验分析
• 市场动态
  • 影响分析
  • 市场驱动因素
  • 市场挑战
  • 市场机会

第二章 全球干性老龄化黄斑部病变市场（按地区）

• 北美洲
• 欧洲
• 亚太地区
  • 主要发现
  • 市场动态
  • 市场规模及预测

3. 全球干性老龄化黄斑部病变市场：竞争格局与公司概况

• 关键发展和策略
• 公司简介
  • AstraZeneca
  • Astellas Pharma
  • Novartis AG.
  • Apellis Pharmaceuticals
  • Alkeus Pharmaceuticals.
  • Belite Bio.
  • Aviceda Therapeutics
  • Cognition Therapeutics
  • Annexon Biosciences
  • Lineage Cell Therapeutics

第四章调查方法

Global Dry Age-Related Macular Degeneration Market, Analysis and Forecast: 2025-2035

Dry age-related macular degeneration is a progressive eye condition that affects the macula, the central part of the retina responsible for sharp, central vision. This condition leads to gradual loss of vision, particularly in the central field of view, which is crucial for activities such as reading, driving, and recognizing faces.

The dry age-related macular degeneration market is witnessing substantial growth, driven by a range of key factors. One of the primary drivers is the aging global population, as age is the most significant risk factor for developing dry age-related macular degeneration. With an increasing number of elderly individuals, the demand for effective treatments and diagnostic tools is on the rise. Additionally, advancements in retinal imaging technologies, such as optical coherence tomography (OCT) and fundus photography, are enabling earlier detection and more precise monitoring of disease progression, driving market growth.

Furthermore, the growing focus on precision medicine and genetic testing is enhancing the ability to tailor treatments to individual patients, thus improving clinical outcomes. The increasing awareness of eye health and the rising adoption of preventive measures, such as lifestyle changes and regular eye screenings, are also stimulating demand. Moreover, the improvement in healthcare infrastructure in emerging markets and the availability of specialized training for ophthalmologists are fuelling the adoption of innovative AMD treatment options. The combination of these drivers is poised to continue supporting the growth of the dry AMD market.

Despite the positive growth trajectory, several challenges continue to impact the global dry age-related macular degeneration market. One of the primary challenges is the high cost of treatment and diagnostic technologies can be a significant barrier. Innovative treatments, especially in the realm of gene therapy, stem cell therapy, and advanced imaging technologies, come with high development and implementation costs. This can limit access to effective therapies in low- and middle-income regions, where healthcare infrastructure may be less developed and resources are limited.

Moreover, lack of effective treatments for the advanced stages of dry AMD. While there are interventions to manage early stages, such as nutritional supplements and lifestyle modifications, there is no cure or approved treatment that can significantly reverse the damage once it progresses to advanced dry AMD or geographic atrophy. This limitation has restricted the market potential for advanced therapies and treatment options.

As the dry age-related macular degeneration market continues to evolve, several emerging trends are expected to significantly influence its future trajectory. The increasing development of innovative treatments, such as gene therapies, retinal implants, and biologic agents targeting disease progression, is poised to provide new hope for patients. Furthermore, advancements in diagnostic technologies, including high-resolution imaging and artificial intelligence-driven tools for early detection, will allow for more precise monitoring and intervention. With the aging global population, particularly in regions with a higher prevalence of AMD, the demand for cost-effective, easy-to-administer, and efficient treatment options will continue to rise. Additionally, increased focus on the role of lifestyle modifications, such as diet and supplements, will shape prevention strategies, offering a holistic approach to managing age-related macular degeneration.

In conclusion, the global dry age-related macular degeneration market is expected to experience steady growth, driven by advancements in therapeutic interventions, heightened awareness, and a focus on early detection. As research and development in this space continue to progress, key stakeholders, including pharmaceutical companies, healthcare providers, and researchers, will play a critical role in improving treatment outcomes and patient quality of life. The market's expansion, coupled with continued innovation, will empower patients with better management tools, reducing the long-term burden of the condition and preserving vision for millions around the world.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Dry Age-Related Macular Degeneration Markets: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Epidemiology of Dry AMD
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Challenges
  • 1.6.4 Market Opportunities

2. Global Dry Age-Related Macular Degeneration Market, by Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 North America Dry Age-Related Macular Degeneration Market, by Country
      • 2.1.3.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Key Findings
  • 2.2.2 Market Dynamics
  • 2.2.3 Market Sizing and Forecast
    • 2.2.3.1 Europe Dry Age-Related Macular Degeneration Market, by Country
      • 2.2.3.1.1 Germany
      • 2.2.3.1.2 U.K.
      • 2.2.3.1.3 France
      • 2.2.3.1.4 Italy
      • 2.2.3.1.5 Spain
• 2.3 Asia Pacific
  • 2.3.1 Key Findings
  • 2.3.2 Market Dynamics
  • 2.3.3 Market Sizing and Forecast
    • 2.3.3.1 Asia Pacific Dry Age-Related Macular Degeneration Market, by Country
      • 2.3.3.1.1 Japan

3. Global Dry Age-Related Macular Degeneration Market: Competitive Landscape and Company Profiles

• 3.1 Key Development and Strategies
  • 3.1.1 Mergers and Acquisitions
  • 3.1.2 Synergistic Activities
  • 3.1.3 Business Expansions and Funding
  • 3.1.4 Product Launches and Approvals
  • 3.1.5 Other Activities
• 3.2 Company Profiles
  • 3.2.1 AstraZeneca
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Target Customers/End-Users
    • 3.2.1.4 Key Personnel
    • 3.2.1.5 Analyst View
  • 3.2.2 Astellas Pharma
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Target Customers/End-Users
    • 3.2.2.4 Key Personnel
    • 3.2.2.5 Analyst View
  • 3.2.3 Novartis AG.
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Target Customers/End-Users
    • 3.2.3.4 Key Personnel
    • 3.2.3.5 Analyst View
  • 3.2.4 Apellis Pharmaceuticals
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products / Product Portfolio
    • 3.2.4.3 Target Customers/End-Users
    • 3.2.4.4 Key Personnel
    • 3.2.4.5 Analyst View
  • 3.2.5 Alkeus Pharmaceuticals.
    • 3.2.5.1 Overview
    • 3.2.5.2 Top Products / Product Portfolio
    • 3.2.5.3 Target Customers/End-Users
    • 3.2.5.4 Key Personnel
    • 3.2.5.5 Analyst View
  • 3.2.6 Belite Bio.
    • 3.2.6.1 Overview
    • 3.2.6.2 Top Products / Product Portfolio
    • 3.2.6.3 Target Customers/End-Users
    • 3.2.6.4 Key Personnel
    • 3.2.6.5 Analyst View
  • 3.2.7 Aviceda Therapeutics
    • 3.2.7.1 Overview
    • 3.2.7.2 Top Products / Product Portfolio
    • 3.2.7.3 Target Customers/End-Users
    • 3.2.7.4 Key Personnel
    • 3.2.7.5 Analyst View
  • 3.2.8 Cognition Therapeutics
    • 3.2.8.1 Overview
    • 3.2.8.2 Top Products / Product Portfolio
    • 3.2.8.3 Target Customers/End-Users
    • 3.2.8.4 Key Personnel
    • 3.2.8.5 Analyst View
  • 3.2.9 Annexon Biosciences
    • 3.2.9.1 Overview
    • 3.2.9.2 Top Products / Product Portfolio
    • 3.2.9.3 Target Customers/End-Users
    • 3.2.9.4 Key Personnel
    • 3.2.9.5 Analyst View
  • 3.2.10 Lineage Cell Therapeutics
    • 3.2.10.1 Overview
    • 3.2.10.2 Top Products / Product Portfolio
    • 3.2.10.3 Target Customers/End-Users
    • 3.2.10.4 Key Personnel
    • 3.2.10.5 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Dry Age-Related Macular Degeneration Market, Market Overview
• Figure: Epidemiology of Dry Age-Related Macular Degeneration
• Figure: Global Dry Age-Related Macular Degeneration Market (by Region), $Million, 2023 and 2035
• Figure: Global Dry Age-Related Macular Degeneration Market Coverage
• Figure: Global Dry Age-Related Macular Degeneration Market Key Trends, Impact Analysis, 2023-2035
• Figure: Global Dry Age-Related Macular Degeneration Market, Competitive Landscape, January 2022-April 2025

List of Tables

• Table: Global Dry Age-Related Macular Degeneration Market, Clinical Trial Analysis,
• Table: Global Dry Age-Related Macular Degeneration Market Dynamics, Impact Analysis
• Table: Global Dry Age-Related Macular Degeneration Market (by Region), $Million, 2023-2035